Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
Syndax Pharmaceuticals (NASDAQ: SNDX) has appointed Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer. Dr. Botwood brings over 25 years of industry experience, most recently serving as Head of Worldwide Medical Oncology at Bristol Myers Squibb. He succeeds Dr. Neil Gallagher, who is departing the company.
Dr. Botwood's extensive background includes senior roles at BMS from 2015-2025, where he oversaw medical activities in oncology, including new asset launches and commercial strategy. Previously, he held leadership positions at AstraZeneca from 2003-2015. His appointment comes as Syndax continues to expand its oncology portfolio, including the recent submission of Revuforj supplemental New Drug Application for relapsed or refractory mNPM1 acute myeloid leukemia.
Syndax Pharmaceuticals (NASDAQ: SNDX) ha nominato il Dr. Nicholas Botwood come Responsabile della Ricerca e Sviluppo e Direttore Medico. Il Dr. Botwood porta con sé oltre 25 anni di esperienza nel settore, avendo recentemente ricoperto il ruolo di Responsabile della Oncologia Medica Mondiale presso Bristol Myers Squibb. Succede al Dr. Neil Gallagher, che sta lasciando l'azienda.
Il Dr. Botwood vanta un ampio background con ruoli di rilievo in BMS dal 2015 al 2025, dove ha supervisionato le attività mediche in oncologia, inclusi il lancio di nuovi prodotti e la strategia commerciale. In precedenza, ha ricoperto posizioni di leadership in AstraZeneca dal 2003 al 2015. La sua nomina avviene mentre Syndax continua a espandere il proprio portafoglio oncologico, compresa la recente presentazione della domanda supplementare di nuovo farmaco per Revuforj, destinato alla leucemia mieloide acuta mNPM1 recidivante o refrattaria.
Syndax Pharmaceuticals (NASDAQ: SNDX) ha nombrado a Dr. Nicholas Botwood como Jefe de Investigación y Desarrollo y Director Médico. El Dr. Botwood aporta más de 25 años de experiencia en la industria, habiendo ocupado recientemente el cargo de Jefe de Oncología Médica Mundial en Bristol Myers Squibb. Sustituye al Dr. Neil Gallagher, quien está dejando la compañía.
El amplio historial del Dr. Botwood incluye cargos senior en BMS desde 2015 hasta 2025, donde supervisó actividades médicas en oncología, incluyendo lanzamientos de nuevos activos y estrategia comercial. Anteriormente, ocupó puestos de liderazgo en AstraZeneca desde 2003 hasta 2015. Su nombramiento se produce mientras Syndax continúa ampliando su cartera oncológica, incluyendo la reciente presentación de la solicitud suplementaria de nuevo fármaco para Revuforj, destinado a la leucemia mieloide aguda mNPM1 en recaída o refractaria.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 Dr. Nicholas Botwood를 연구개발 책임자 겸 최고 의료 책임자로 임명했습니다. Botwood 박사는 25년이 넘는 업계 경험을 보유하고 있으며, 최근에는 Bristol Myers Squibb에서 전 세계 의료 종양학 책임자로 근무했습니다. 그는 회사를 떠나는 Dr. Neil Gallagher의 후임입니다.
Botwood 박사는 2015년부터 2025년까지 BMS에서 종양학 분야의 의료 활동을 총괄하며 신약 출시 및 상업 전략을 담당하는 고위직을 역임했습니다. 이전에는 2003년부터 2015년까지 AstraZeneca에서 리더십 직책을 맡았습니다. 그의 임명은 Syndax가 재발성 또는 불응성 mNPM1 급성 골수성 백혈병 치료제 Revuforj 보충 신약 신청서를 최근 제출하는 등 종양학 포트폴리오를 확장하는 가운데 이루어졌습니다.
Syndax Pharmaceuticals (NASDAQ: SNDX) a nommé Dr Nicholas Botwood au poste de Directeur de la Recherche et Développement et Directeur Médical. Le Dr Botwood apporte plus de 25 ans d'expérience dans l'industrie, ayant récemment occupé le poste de Responsable mondial de l'oncologie médicale chez Bristol Myers Squibb. Il succède au Dr Neil Gallagher, qui quitte l'entreprise.
Le parcours étendu du Dr Botwood comprend des postes de direction chez BMS de 2015 à 2025, où il a supervisé les activités médicales en oncologie, y compris le lancement de nouveaux actifs et la stratégie commerciale. Auparavant, il a occupé des postes de direction chez AstraZeneca de 2003 à 2015. Sa nomination intervient alors que Syndax continue d'élargir son portefeuille oncologique, notamment avec la récente soumission de la demande d'autorisation de mise sur le marché complémentaire pour Revuforj, destiné à la leucémie myéloïde aiguë mNPM1 en rechute ou réfractaire.
Syndax Pharmaceuticals (NASDAQ: SNDX) hat Dr. Nicholas Botwood zum Leiter der Forschung und Entwicklung sowie zum Chief Medical Officer ernannt. Dr. Botwood verfügt über mehr als 25 Jahre Branchenerfahrung und war zuletzt Leiter der weltweiten medizinischen Onkologie bei Bristol Myers Squibb. Er tritt die Nachfolge von Dr. Neil Gallagher an, der das Unternehmen verlässt.
Dr. Botwoods umfangreiche Erfahrung umfasst Führungspositionen bei BMS von 2015 bis 2025, wo er medizinische Aktivitäten in der Onkologie leitete, einschließlich der Einführung neuer Produkte und der kommerziellen Strategie. Zuvor hatte er Führungsrollen bei AstraZeneca von 2003 bis 2015 inne. Seine Ernennung erfolgt, während Syndax sein Onkologie-Portfolio weiter ausbaut, darunter die kürzliche Einreichung des ergänzenden Zulassungsantrags für Revuforj zur Behandlung des rezidivierten oder refraktären mNPM1-akuten myeloischen Leukämie.
- Appointment of highly experienced executive with 25 years of industry expertise in oncology
- Strong track record in developing and commercializing oncology products from previous roles at BMS and AstraZeneca
- Recent progress with Revuforj sNDA submission indicates ongoing pipeline advancement
- Departure of current CMO Dr. Neil Gallagher creates potential transition risks
- Leadership change may temporarily impact ongoing R&D initiatives
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics -
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversaw all medical activities in its oncology portfolio, including new asset launches, data generation, medical education and commercial strategy. Dr. Botwood will drive Syndax's R&D strategy and development, succeeding Dr. Neil Gallagher, who is departing to pursue other opportunities.
“Nick is a prominent leader and R&D visionary who brings deep strategic and operational experience, and a proven track record of developing novel medicines into industry-leading franchises,” said Michael A. Metzger, Chief Executive Officer. “Nick’s unique mix of commercial, medical and clinical oncology development experience will enable us to accelerate the expansion of our two best-in-class franchises and fully unlock their multi-billion potential. We look forward to his many contributions.”
Prior to joining Syndax, Dr. Botwood served as Senior Vice President, Head of Worldwide Medical Oncology at Bristol Myers Squibb since 2022. From 2022 to 2020, he served as Senior Vice President, Head U.S. Medical where he was accountable for the medical strategy in the United States across commercial and development, including hematology and oncology. Prior to this role, Dr. Botwood held senior clinical development roles at Bristol Myers Squibb from 2015 to 2020, including Head of Oncology Clinical Development and Development Team Lead. Prior to Bristol Myers Squibb, he joined AstraZeneca from 2003 to 2015, where he took on the role of Vice President, Head of Oncology Clinical and Head of Global Clinical Operations. Dr. Botwood holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Imperial College London and a Bachelor of Science (BSc) from University College London. He is a member of the Faculty of Pharmaceutical Medicine and an elected Fellow of the Royal College of Physicians UK.
“Syndax is a proven innovator at the forefront of oncology with medicines that address some of the toughest challenges in treating cancer,” said Dr. Botwood. “The Company has an impressive track record of developing and commercializing first- and best-in-class medicines and driving execution across its portfolio, with a robust development strategy underway for expansion and to further differentiate its drugs. I look forward to working alongside the talented team at Syndax to support its commitment to innovation and shape the future of cancer treatment.”
Mr. Metzger added, “We thank Neil for his exceptional contributions during his time at Syndax, which include multiple positive data readouts and two product approvals, along with the recent submission of the Revuforj supplemental New Drug Application for relapsed or refractory mNPM1 acute myeloid leukemia. Neil built a strong R&D organization that will continue to deliver on our ambitious plans for the future, and accordingly, we are in an excellent position to transition R&D leadership to Nick, who will spearhead this next chapter of growth for Syndax.”
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
Who is the new Chief Medical Officer of Syndax Pharmaceuticals (SNDX)?
What was Dr. Nicholas Botwood's previous role before joining SNDX?
Why did Syndax Pharmaceuticals (SNDX) change its Chief Medical Officer?
What are Dr. Nicholas Botwood's key achievements and qualifications?
What recent developments has SNDX announced regarding its drug pipeline?
